FDA Accepts Supplement Application for COLUMVI (GLOFITAMAB-GXBM)
The FDA has accepted the supplemental application for COLUMVI, a bispecific T-cell engager.
Asset / Drug
Drug and asset intelligence for COLUMVI with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
July 8, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.